Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?

Intern Emerg Med. 2020 Aug;15(5):801-812. doi: 10.1007/s11739-020-02383-3. Epub 2020 May 26.

Abstract

Of huge importance now is to provide a fast, cost-effective, safe, and immediately available pharmaceutical solution to curb the rapid global spread of SARS-CoV-2. Recent publications on SARS-CoV-2 have brought attention to the possible benefit of chloroquine in the treatment of patients infected by SARS-CoV-2. Whether chloroquine can treat SARS-CoV-2 alone and also work as a prophylactic is doubtful. An effective prophylactic medication to prevent viral entry has to contain, at least, either a protease inhibitor or a competitive virus ACE2-binding inhibitor. Using bromhexine at a dosage that selectively inhibits TMPRSS2 and, in so doing, inhibits TMPRSS2-specific viral entry is likely to be effective against SARS-CoV-2. We propose the use of bromhexine as a prophylactic and treatment. We encourage the scientific community to assess bromhexine clinically as a prophylactic and curative treatment. If proven to be effective, this would allow a rapid, accessible, and cost-effective application worldwide.

Keywords: Bromhexine; COVID-19; Prophylactic; Protease inhibitor; SARS-CoV-2; Treatment.

Publication types

  • Review

MeSH terms

  • Betacoronavirus
  • Bromhexine / therapeutic use*
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Expectorants / therapeutic use*
  • Humans
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2
  • Serine Endopeptidases / drug effects*
  • Virus Internalization / drug effects

Substances

  • Expectorants
  • Serine Endopeptidases
  • TMPRSS2 protein, human
  • Bromhexine